Also based on these results, it is possible to state that the approach proposed here is producing biologically relevant results that can be utilized in drug discovery and repurposing studies beyond PI3K/Akt/mTOR pathway and cancer, especially for pathological conditions where specific domain-based targeting may be critical, such as metabolic disorders. The gene discussed is AKT1; the disease is metabolic disease.